Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Matthew Raymond Smith, M.D., PH.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K24CA121990 (SMITH, MATTHEW RAYMOND) Jul 6, 2006 - Jul 31, 2017
    NIH/NCI
    Midcareer Investigator Award
    Role: Principal Investigator
  2. R21CA101353 (SMITH, MATTHEW RAYMOND) Sep 1, 2003 - Aug 31, 2005
    NIH/NCI
    ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy
    Role: Principal Investigator
  3. M01RR001066 (SLAVIN, PETER L) Feb 1, 1978 - May 31, 2008
    NIH/NCRR
    General Clinical Research Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Mar; 20(3):408-419. PMID: 30738780.
    Citations:    
  2. Smith MR, Yu MK, Small EJ. Apalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 06 28; 378(26):2542. PMID: 29949495.
    Citations: 1     Fields:    Translation:Humans
  3. Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baron B, Krivoshik A, Hirmand M, Smith MR. Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results. J Urol. 2018 Feb; 199(2):459-464. PMID: 28867562.
    Citations: 2     Fields:    
  4. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 07; 72(1):10-13. PMID: 28314611.
    Citations: 2     Fields:    Translation:HumansCells
  5. Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, De Porre P, Vermeulen A, Poggesi I, Nandy P. Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Pharmacokinet. 2017 01; 56(1):55-63. PMID: 27324190.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  6. Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, Keating NL, Smith MR, Zhou Y, Aaronson DS, Potosky AL. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 06; 197(6):1448-1454. PMID: 28007467.
    Citations: 1     Fields:    
  7. Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 09 01; 34(25):3005-13. PMID: 27400947.
    Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
  8. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 04; 71(4):656-664. PMID: 27402060.
    Citations: 4     Fields:    Translation:Humans
  9. Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. Eur Urol. 2016 12; 70(6):963-970. PMID: 27160947.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  10. Lipton A, Smith MR, Fizazi K, Stopeck AT, Henry D, Brown JE, Shore ND, Saad F, Spencer A, Zhu L, Warner DJ. Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clin Cancer Res. 2016 Dec 01; 22(23):5713-5721. PMID: 27140926.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  11. Fu AZ, Tsai HT, Haque R, Ulcickas Yood M, Van Den Eeden SK, Cassidy-Bushrow AE, Zhou Y, Keating NL, Smith MR, Aaronson DS, Potosky AL. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer. World J Urol. 2016 Dec; 34(12):1611-1619. PMID: 27084777.
    Citations: 1     Fields:    Translation:Humans
  12. Voog JC, Smith MR, Efstathiou JA. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2016 Mar 08; 315(10):1054-5. PMID: 26954419.
    Citations:    Fields:    Translation:Humans
  13. Krzywanski DM, Moellering DR, Westbrook DG, Dunham-Snary KJ, Brown J, Bray AW, Feeley KP, Sammy MJ, Smith MR, Schurr TG, Vita JA, Ambalavanan N, Calhoun D, Dell'Italia L, Ballinger SW. Endothelial Cell Bioenergetics and Mitochondrial DNA Damage Differ in Humans Having African or West Eurasian Maternal Ancestry. Circ Cardiovasc Genet. 2016 Feb; 9(1):26-36. PMID: 26787433; PMCID: PMC4758889.
    Citations: 6     Fields:    Translation:HumansCells
  14. Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32. PMID: 26508309.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  15. Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DA. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015 Sep 18; 349(6254):1351-6. PMID: 26383955; PMCID: PMC4872391.
    Citations: 97     Fields:    Translation:HumansAnimalsCells
  16. Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol. 2016 Feb; 69(2):204-10. PMID: 26362090; PMCID: PMC4784682.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  17. Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2015 Nov; 194(5):1277-84. PMID: 26151676.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  18. Gartrell BA, Coleman R, Efstathiou E, Fizazi K, Logothetis CJ, Smith MR, Sonpavde G, Sartor O, Saad F. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. Eur Urol. 2015 Nov; 68(5):850-8. PMID: 26153564.
    Citations: 5     Fields:    Translation:Humans
  19. Preston MA, Feldman AS, Coen JJ, McDougal WS, Smith MR, Paly JJ, Carrasquillo R, Wu CL, Dahl DM, Barrisford GW, Blute ML, Zietman AI. Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. Urol Oncol. 2015 Sep; 33(9):383.e9-16. PMID: 26059076.
    Citations: 1     Fields:    Translation:Humans
  20. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7. PMID: 25985882.
    Citations: 5     Fields:    Translation:Humans
  21. Xu XS, Ryan CJ, Stuyckens K, Smith MR, Saad F, Griffin TW, Park YC, Yu MK, Vermeulen A, Poggesi I, Nandy P. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clin Cancer Res. 2015 Jul 15; 21(14):3170-7. PMID: 25829400.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  22. Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Baron B, Hirmand M, Smith MR. Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. Eur Urol. 2015 Nov; 68(5):787-94. PMID: 25687533.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  23. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60. PMID: 25601341.
    Citations: 143     Fields:    Translation:HumansCTClinical Trials
  24. Tsai HT, Keating NL, Van Den Eeden SK, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Smith MR, Potosky AL. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. J Urol. 2015 Jun; 193(6):1956-62. PMID: 25524243; PMCID: PMC4543371.
    Citations: 7     Fields:    Translation:Humans
  25. Stuyckens K, Saad F, Xu XS, Ryan CJ, Smith MR, Griffin TW, Yu MK, Vermeulen A, Nandy P, Poggesi I. Population pharmacokinetic analysis of abiraterone in chemotherapy-naïve and docetaxel-treated patients with metastatic castration-resistant prostate cancer. Clin Pharmacokinet. 2014 Dec; 53(12):1149-60. PMID: 25204404.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  26. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015 Feb; 26(2):368-74. PMID: 25425475; PMCID: PMC4304378.
    Citations: 25     Fields:    Translation:HumansCTClinical Trials
  27. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20; 32(30):3391-9. PMID: 25225437.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  28. Smith MR, Halabi S, Small EJ. Reply to F. Valcamonico et al. J Clin Oncol. 2014 Nov 10; 32(32):3685. PMID: 25225438.
    Citations:    Fields:    Translation:Humans
  29. Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May; 67(5):825-36. PMID: 25097095.
    Citations: 62     Fields:    Translation:Humans
  30. Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, Wang SL, Paolini J, Chen I, Chow-Maneval E, Mooney DJ, Lechuga M, Smith MR, Michaelson MD. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int. 2014 Dec; 114(6b):E25-E31. PMID: 24298897.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  31. Padhi D, Higano CS, Shore ND, Sieber P, Rasmussen E, Smith MR. Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2014 Oct; 99(10):E1967-75. PMID: 24971661.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  32. Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol. 2014 May; 15(6):592-600. PMID: 24739897.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  33. Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. J Clin Oncol. 2014 May 01; 32(13):1324-30. PMID: 24638009; PMCID: PMC3992722.
    Citations: 16     Fields:    Translation:Humans
  34. Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ, Wang SL, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith MR, Michaelson MD. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014 Oct; 12(5):317-24. PMID: 24806399.
    Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
  35. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. PMID: 24647231; PMCID: PMC4418928.
    Citations: 54     Fields:    Translation:HumansCTClinical Trials
  36. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50. PMID: 24590644; PMCID: PMC3970172.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  37. Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb; 67(2):310-8. PMID: 24631409.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  38. Smith MR. Androgen deprivation therapy and acute kidney injury. JAMA. 2013 Dec 04; 310(21):2313. PMID: 24302098.
    Citations:    Fields:    Translation:Humans
  39. Lee RJ, Smith MR. Cabozantinib and prostate cancer: inhibiting seed and disrupting soil? Clin Cancer Res. 2014 Feb 01; 20(3):525-7. PMID: 24284057; PMCID: PMC3966545.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  40. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1193-9. PMID: 24075621.
    Citations: 34     Fields:    Translation:HumansCTClinical Trials
  41. Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, Tombal B, Damiao R, Marx G, Miller K, Van Veldhuizen P, Morote J, Ye Z, Dansey R, Goessl C. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol. 2013 Oct 20; 31(30):3800-6. PMID: 24043751; PMCID: PMC3795889.
    Citations: 32     Fields:    Translation:Humans
  42. Smith MR. Cancer: ADT and acute kidney injury-causal or casual relationship? Nat Rev Endocrinol. 2013 Oct; 9(10):568-70. PMID: 23959367.
    Citations:    Fields:    Translation:HumansAnimals
  43. Taksler GB, Cutler DM, Giovannucci E, Smith MR, Keating NL. Ultraviolet index and racial differences in prostate cancer incidence and mortality. Cancer. 2013 Sep 01; 119(17):3195-203. PMID: 23744754.
    Citations: 5     Fields:    Translation:Humans
  44. Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MR. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94. PMID: 23553848; PMCID: PMC3684567.
    Citations: 33     Fields:    Translation:HumansCells
  45. Keating NL, Liu PH, O'Malley AJ, Freedland SJ, Smith MR. Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014 Apr; 65(4):816-24. PMID: 23453420; PMCID: PMC3779484.
    Citations: 14     Fields:    Translation:Humans
  46. Saylor PJ, Smith MR, O'Malley AJ, Keating NL. Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer. Eur Urol. 2014 Mar; 65(3):642-9. PMID: 23428068; PMCID: PMC4535925.
    Citations:    Fields:    Translation:Humans
  47. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S45-50. PMID: 23234631.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  48. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PMID: 23234628.
    Citations: 30     Fields:    Translation:Humans
  49. Lee RJ, Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer. Cancer J. 2013 Jan-Feb; 19(1):90-8. PMID: 23337762; PMCID: PMC3683553.
    Citations: 17     Fields:    Translation:HumansCells
  50. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. PMID: 23228172; PMCID: PMC3683570.
    Citations: 441     Fields:    Translation:Humans
  51. Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol. 2013 Feb; 63(2):309-20. PMID: 23201471; PMCID: PMC3661203.
    Citations: 11     Fields:    Translation:Humans
  52. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9. PMID: 23169517; PMCID: PMC4110249.
    Citations: 126     Fields:    Translation:HumansCTClinical Trials
  53. Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DA. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003. PMID: 23093251; PMCID: PMC3508523.
    Citations: 80     Fields:    Translation:HumansCells
  54. Morgans AK, Smith MR, O'Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer. 2013 Feb 15; 119(4):863-70. PMID: 23065626; PMCID: PMC3671351.
    Citations: 12     Fields:    Translation:Humans
  55. Keating NL, O'Malley A, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2012 Oct 03; 104(19):1518-23. PMID: 23210129; PMCID: PMC3634556.
    Citations: 23     Fields:    Translation:Humans
  56. Saylor PJ, Mahmood U, Kunawudhi A, Smith MR, Palmer EL, Michaelson MD. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med. 2012 Nov; 53(11):1670-5. PMID: 22984218; PMCID: PMC3755364.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  57. Morgans AK, Smith MR. Bone-targeted agents: preventing skeletal complications in prostate cancer. Urol Clin North Am. 2012 Nov; 39(4):533-46. PMID: 23084529; PMCID: PMC3721069.
    Citations: 4     Fields:    Translation:HumansCells
  58. D'Amico AV, Smith MR. Clinical decisions. Screening for prostate cancer. N Engl J Med. 2012 Aug 16; 367(7):e11. PMID: 22894598; PMCID: PMC3703939.
    Citations: 1     Fields:    Translation:Humans
  59. Lipton A, Smith MR, Ellis GK, Goessl C. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol. 2012; 6:287-303. PMID: 22933844; PMCID: PMC3427033.
    Citations: 6     
  60. Smith MR. Skeletal-related events in prostate cancer. Clin Adv Hematol Oncol. 2012 Aug; 10(8):535-6. PMID: 23073052.
    Citations:    Fields:    Translation:Humans
  61. Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Sep 10; 30(26):3271-6. PMID: 22649143; PMCID: PMC3434987.
    Citations: 18     Fields:    Translation:Humans
  62. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012 Jul 01; 18(13):3677-85. PMID: 22589396; PMCID: PMC3661207.
    Citations: 17     Fields:    Translation:HumansCells
  63. Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee KA, Coleman RE, Smith MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist. 2012; 17(5):645-52. PMID: 22523198; PMCID: PMC3360904.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  64. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol. 2013 Jul; 64(1):159-66. PMID: 22537796; PMCID: PMC3683550.
    Citations: 9     Fields:    Translation:Humans
  65. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9. PMID: 22302227; PMCID: PMC3286170.
    Citations: 13     Fields:    Translation:Humans
  66. Hu JC, Williams SB, O'Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012 Jun; 61(6):1119-28. PMID: 22336376; PMCID: PMC3719131.
    Citations: 17     Fields:    Translation:Humans
  67. Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2012 Mar; 187(3):889-93. PMID: 22245322; PMCID: PMC3671868.
    Citations: 6     Fields:    Translation:Humans
  68. Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl C. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec; 26(12):2827-33. PMID: 21898590; PMCID: PMC3222788.
    Citations: 8     Fields:    Translation:Humans
  69. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damião R, Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gómez-Veiga F, Borkowski T, Ye Z, Kupic A, Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 07; 379(9810):39-46. PMID: 22093187; PMCID: PMC3671878.
    Citations: 201     Fields:    Translation:HumansCTClinical Trials
  70. Smith MR, Malkowicz SB, Brawer MK, Hancock ML, Morton RA, Steiner MS. Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. J Urol. 2011 Dec; 186(6):2239-44. PMID: 22014807; PMCID: PMC3671875.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  71. Morgans AK, Smith MR. RANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis. J Osteoporos. 2011; 2011:941310. PMID: 22013547; PMCID: PMC3196262.
    Citations: 3     
  72. Smith MR, Klotz L, van der Meulen E, Colli E, Tankó LB. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011 Nov; 186(5):1835-42. PMID: 21944083; PMCID: PMC3712275.
    Citations: 11     Fields:    Translation:Humans
  73. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011 Sep 20; 29(27):3705-14. PMID: 21860001.
    Citations: 30     Fields:    Translation:Humans
  74. Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS, Smith MR. Factors associated with vertebral fractures in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2011 Aug; 186(2):482-6. PMID: 21679977; PMCID: PMC3669546.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  75. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. PMID: 21632851; PMCID: PMC3657705.
    Citations: 67     Fields:    Translation:HumansCTClinical Trials
  76. Smith MR, Zietman AL, Finkelstein JS, Wu CL. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer. N Engl J Med. 2011 May 26; 364(21):2044-51. PMID: 21612474.
    Citations:    Fields:    Translation:Humans
  77. Smith MR. Effective treatment for early-stage prostate cancer--possible, necessary, or both? N Engl J Med. 2011 May 05; 364(18):1770-2. PMID: 21542749.
    Citations: 5     Fields:    Translation:Humans
  78. Hatoum HT, Lin SJ, Smith MR, Guo A, Lipton A. Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis. Clin Breast Cancer. 2011 Jun; 11(3):177-83. PMID: 21665138.
    Citations: 6     Fields:    Translation:Humans
  79. Saylor PJ, Keating NL, Freedland SJ, Smith MR. Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer. Drugs. 2011 Feb 12; 71(3):255-61. PMID: 21319864; PMCID: PMC3671348.
    Citations: 1     Fields:    Translation:Humans
  80. Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol. 2012 Jul-Aug; 30(4):369-78. PMID: 21163673; PMCID: PMC3107360.
    Citations: 6     Fields:    Translation:Humans
  81. Lee RJ, Saylor PJ, Smith MR. Contemporary therapeutic approaches targeting bone complications in prostate cancer. Clin Genitourin Cancer. 2010 Dec 01; 8(1):29-36. PMID: 21208853; PMCID: PMC3090680.
    Citations: 11     Fields:    Translation:HumansCells
  82. Hatoum HT, Lin SJ, Guo A, Lipton A, Smith MR. Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis. Curr Med Res Opin. 2011 Jan; 27(1):55-62. PMID: 21083514; PMCID: PMC3047395.
    Citations: 7     Fields:    Translation:Humans
  83. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer. 2011 May 15; 117(10):2077-85. PMID: 21523719; PMCID: PMC3116053.
    Citations: 36     Fields:    Translation:Humans
  84. Smith MR, Klotz L, Persson BE, Olesen TK, Wilde AA. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol. 2010 Dec; 184(6):2313-9. PMID: 20952020; PMCID: PMC3047399.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  85. Kim HS, Moreira DM, Smith MR, Presti JC, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int. 2011 Mar; 107(6):924-8. PMID: 20860651; PMCID: PMC3055926.
    Citations: 12     Fields:    Translation:Humans
  86. Coen JJ, Feldman AS, Smith MR, Zietman AL. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int. 2011 May; 107(10):1582-6. PMID: 20860650; PMCID: PMC3082632.
    Citations: 6     Fields:    Translation:Humans
  87. Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS. Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2010 Oct; 184(4):1316-21. PMID: 20723926; PMCID: PMC3047407.
    Citations: 39     Fields:    Translation:HumansCTClinical Trials
  88. Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res. 2010 Aug 15; 16(16):4084-93. PMID: 20643782.
    Citations: 12     Fields:    Translation:Humans
  89. Faris JE, Smith MR. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2010 Jun; 17(3):240-6. PMID: 20404727.
    Citations: 11     Fields:    Translation:Humans
  90. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol. 2010 Jun; 183(6):2200-5. PMID: 20399451; PMCID: PMC2900634.
    Citations: 15     Fields:    Translation:Humans
  91. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone. 2011 Jan; 48(1):88-95. PMID: 20621630; PMCID: PMC3010497.
    Citations: 28     Fields:    Translation:HumansCells
  92. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clézardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010 Dec; 36(8):615-20. PMID: 20478658; PMCID: PMC3047387.
    Citations: 46     Fields:    Translation:HumansAnimalsPHPublic Health
  93. Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran S. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23. PMID: 20424012; PMCID: PMC3141292.
    Citations: 162     Fields:    Translation:HumansCells
  94. Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int. 2010 May; 105(10):1417-22. PMID: 20346051; PMCID: PMC3090683.
    Citations: 5     Fields:    Translation:Humans
  95. Efstathiou JA, Shipley WU, Zietman AL, Smith MR. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol. 2010 Mar; 7(3):130-2. PMID: 20190794; PMCID: PMC2900769.
    Citations: 1     Fields:    Translation:Humans
  96. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8. PMID: 20159824; PMCID: PMC2849769.
    Citations: 124     Fields:    Translation:HumansCTClinical Trials
  97. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 20; 28(9):1496-501. PMID: 20159814.
    Citations: 139     Fields:    Translation:HumansCellsCTClinical Trials
  98. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201. PMID: 20124400; PMCID: PMC3049943.
    Citations: 45     Fields:    Translation:Humans
  99. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010 Feb 16; 121(6):833-40. PMID: 20124128; PMCID: PMC3023973.
    Citations: 54     Fields:    Translation:Humans
  100. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P, Walsh PC. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):162-200. PMID: 20141676.
    Citations: 186     Fields:    Translation:Humans
  101. Saylor PJ, Smith MR. Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. J Natl Compr Canc Netw. 2010 Feb; 8(2):211-23. PMID: 20141678; PMCID: PMC2900630.
    Citations: 16     Fields:    Translation:Humans
  102. Smith MR, Kantoff PW. Changes in PSA kinetics after DNA vaccine therapy-not so fast! J Clin Oncol. 2010 Feb 01; 28(4):e58; author reply e59. PMID: 20008614.
    Citations: 2     Fields:    Translation:Humans
  103. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010 Jan 06; 102(1):39-46. PMID: 19996060; PMCID: PMC3107568.
    Citations: 124     Fields:    Translation:Humans
  104. Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009 Dec; 182(6):2670-5. PMID: 19836774; PMCID: PMC2900763.
    Citations: 19     Fields:    Translation:Humans
  105. Saylor PJ, Keating NL, Smith MR. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S389-94. PMID: 19838837; PMCID: PMC2763167.
    Citations: 15     Fields:    Translation:Humans
  106. Saylor PJ, Smith MR. Prostate cancer: How can we improve the health of men who receive ADT? Nat Rev Urol. 2009 Oct; 6(10):529-31. PMID: 19806171; PMCID: PMC2900772.
    Citations: 2     Fields:    Translation:Humans
  107. Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, Smith MR. The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors. J Natl Compr Canc Netw. 2009 Oct; 7 Suppl 7:S1-29; quiz S30. PMID: 19878635; PMCID: PMC3047391.
    Citations: 21     Fields:    Translation:Humans
  108. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20; 361(8):745-55. PMID: 19671656; PMCID: PMC3038121.
    Citations: 242     Fields:    Translation:Humans
  109. Major PP, Cook RJ, Lipton A, Smith MR, Terpos E, Coleman RE. Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. BMC Cancer. 2009 Aug 06; 9:272. PMID: 19660124; PMCID: PMC2739221.
    Citations: 14     Fields:    Translation:Humans
  110. Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, Shapiro CL, Shields A, Smith MR, Srinivas S, Van Poznak CH. NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009 Jun; 7 Suppl 3:S1-32; quiz S33-5. PMID: 19555589; PMCID: PMC3047404.
    Citations: 62     Fields:    Translation:HumansPHPublic Health
  111. Temel JS, Greer JA, Goldberg S, Vogel PD, Sullivan M, Pirl WF, Lynch TJ, Christiani DC, Smith MR. A structured exercise program for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 May; 4(5):595-601. PMID: 19276834; PMCID: PMC2975103.
    Citations: 31     Fields:    Translation:Humans
  112. Lipton A, Brown GA, Mundy GR, Roodman GD, Smith MR. New opportunities for the management of cancer-related bone complications. Clin Adv Hematol Oncol. 2009 May; 7(5 Suppl 11):1-30; quiz 31. PMID: 19741583.
    Citations:    Fields:    Translation:Humans
  113. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009 May; 181(5):1998-2006; discussion 2007-8. PMID: 19286225; PMCID: PMC2900631.
    Citations: 56     Fields:    Translation:Humans
  114. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009 Jan 01; 27(1):92-9. PMID: 19047297; PMCID: PMC2645096.
    Citations: 65     Fields:    Translation:HumansCTClinical Trials
  115. Coleman RE, Guise TA, Lipton A, Roodman GD, Berenson JR, Body JJ, Boyce BF, Calvi LM, Hadji P, McCloskey EV, Saad F, Smith MR, Suva LJ, Taichman RS, Vessella RL, Weilbaecher KN. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res. 2008 Oct 15; 14(20):6387-95. PMID: 18927277; PMCID: PMC2763638.
    Citations: 21     Fields:    Translation:Humans
  116. Isbarn H, Boccon-Gibod L, Carroll PR, Montorsi F, Schulman C, Smith MR, Sternberg CN, Studer UE. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Eur Urol. 2009 Jan; 55(1):62-75. PMID: 18945543; PMCID: PMC3090670.
    Citations: 20     Fields:    Translation:Humans
  117. Smith MR. Osteoporosis in men with prostate cancer: now for the fracture data. J Clin Oncol. 2008 Sep 20; 26(27):4371-2. PMID: 18802147.
    Citations:    Fields:    Translation:Humans
  118. Smith MR, Bae K, Efstathiou JA, Hanks GE, Pilepich MV, Sandler HM, Shipley WU. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol. 2008 Sep 10; 26(26):4333-9. PMID: 18779620; PMCID: PMC2653118.
    Citations: 24     Fields:    Translation:Humans
  119. Smith MR. Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond. Urol Oncol. 2008 Jul-Aug; 26(4):420-5. PMID: 18593621; PMCID: PMC3090666.
    Citations: 11     Fields:    Translation:HumansCells
  120. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34(7):629-39. PMID: 18579314; PMCID: PMC3090688.
    Citations: 29     Fields:    Translation:Humans
  121. Smith MR. Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past? J Clin Oncol. 2008 Jun 20; 26(18):2932-3. PMID: 18565878.
    Citations:    Fields:    Translation:HumansAnimals
  122. Smith MR, O'Malley AJ, Keating NL. Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome? BJU Int. 2008 Jun; 101(11):1335-6. PMID: 18454791; PMCID: PMC3047398.
    Citations: 4     Fields:    Translation:Humans
  123. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008 Jul-Aug; 58(4):196-213. PMID: 18502900; PMCID: PMC2900775.
    Citations: 36     Fields:    Translation:HumansPHPublic Health
  124. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer. 2008 May 15; 112(10):2188-94. PMID: 18348297; PMCID: PMC2562782.
    Citations: 45     Fields:    Translation:Humans
  125. Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep. 2008 May; 9(3):197-202. PMID: 18765113; PMCID: PMC3047401.
    Citations: 7     Fields:    Translation:Humans
  126. Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MS. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008 Apr 10; 26(11):1824-9. PMID: 18398147; PMCID: PMC3049948.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  127. Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol. 2008 Mar; 3(3):228-36. PMID: 18317064.
    Citations: 35     Fields:    Translation:HumansCellsCTClinical Trials
  128. Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008 Feb; 71(2):318-22. PMID: 18308111; PMCID: PMC2614378.
    Citations: 44     Fields:    Translation:Humans
  129. Pirl WF, Greer JA, Goode M, Smith MR. Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology. 2008 Feb; 17(2):148-53. PMID: 17443645; PMCID: PMC3047392.
    Citations: 9     Fields:    Translation:Humans
  130. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol. 2008 Oct; 54(4):816-23. PMID: 18243498.
    Citations: 53     Fields:    Translation:Humans
  131. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83. PMID: 18190632; PMCID: PMC2900629.
    Citations: 5     Fields:    Translation:Humans
  132. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner M. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9. PMID: 18097410; PMCID: PMC3090667.
    Citations: 750     Fields:    Translation:HumansCells
  133. Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman ML. Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7. PMID: 17721994; PMCID: PMC3090684.
    Citations: 25     Fields:    Translation:Humans
  134. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007 Dec 15; 110(12):2691-9. PMID: 17999404; PMCID: PMC3047389.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  135. Smith MR, Malkowicz SB, Chu F, Forrest J, Price D, Sieber P, Barnette KG, Rodriguez D, Steiner MS. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008 Jan; 179(1):152-5. PMID: 18001802; PMCID: PMC3090686.
    Citations: 32     Fields:    Translation:HumansCTClinical Trials
  136. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007 Sep; 12(9):1035-43. PMID: 17914073.
    Citations: 27     Fields:    Translation:HumansCellsCTClinical Trials
  137. Smith MR, Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology. 2007 Aug; 70(2):315-9. PMID: 17826496; PMCID: PMC3047396.
    Citations: 15     Fields:    Translation:Humans
  138. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes. 2007 Jun; 14(3):247-54. PMID: 17940447; PMCID: PMC3047388.
    Citations: 46     Fields:    Translation:Humans
  139. Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007 Mar 20; 25(9):1038-42. PMID: 17369566; PMCID: PMC3047397.
    Citations: 75     Fields:    Translation:Humans
  140. Lipton A, Cook RJ, Coleman RE, Smith MR, Major P, Terpos E, Berenson JR. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma. Clin Lymphoma Myeloma. 2007 Mar; 7(5):346-53. PMID: 17562244.
    Citations: 8     Fields:    Translation:Humans
  141. Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin Cancer Res. 2007 Jan 01; 13(1):241-5. PMID: 17200361; PMCID: PMC3047403.
    Citations: 27     Fields:    Translation:Humans
  142. Smith MR. Treatment-related osteoporosis in men with prostate cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6315s-6319s. PMID: 17062721; PMCID: PMC3047394.
    Citations: 9     Fields:    Translation:Humans
  143. Lipton A, Berenson JR, Body JJ, Boyce BF, Bruland OS, Carducci MA, Cleeland CS, Clohisy DR, Coleman RE, Cook RJ, Guise TA, Pearse RN, Powles TJ, Rogers MJ, Roodman GD, Smith MR, Suva LJ, Vessella RL, Weilbaecher KN, King L. Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 2):6209s-6212s. PMID: 17062702; PMCID: PMC2705325.
    Citations: 4     Fields:    Translation:Humans
  144. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006 Sep 20; 24(27):4448-56. PMID: 16983113.
    Citations: 311     Fields:    Translation:Humans
  145. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 01; 107(3):530-5. PMID: 16804927.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  146. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8. PMID: 16782912.
    Citations: 39     Fields:    Translation:Humans
  147. Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, Saad F, Smith MR. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3361-7. PMID: 16740758.
    Citations: 45     Fields:    Translation:Humans
  148. Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA. Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar; 15(3):293-305. PMID: 16503765.
    Citations: 7     Fields:    Translation:Humans
  149. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006 Apr; 91(4):1305-8. PMID: 16434464.
    Citations: 119     Fields:    Translation:Humans
  150. Smith MR. Markers of bone metabolism in prostate cancer. Cancer Treat Rev. 2006; 32 Suppl 1:23-6. PMID: 16680835.
    Citations: 5     Fields:    Translation:Humans
  151. Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006 Jan; 175(1):136-9; discussion 139. PMID: 16406890.
    Citations: 57     Fields:    Translation:Humans
  152. Smith MR. Therapy Insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol. 2005 Dec; 2(12):608-15; quiz 628. PMID: 16474548.
    Citations: 3     Fields:    Translation:Humans
  153. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005 Nov 10; 23(32):8219-24. PMID: 16278476.
    Citations: 27     Fields:    Translation:Humans
  154. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005 Nov 01; 23(31):7897-903. PMID: 16258089.
    Citations: 87     Fields:    Translation:Humans
  155. Lee H, McGovern K, Finkelstein JS, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer. 2005 Oct 15; 104(8):1633-7. PMID: 16116596.
    Citations: 39     Fields:    Translation:Humans
  156. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005; 31 Suppl 3:19-25. PMID: 16229955.
    Citations: 20     Fields:    Translation:Humans
  157. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 01; 23(13):2918-25. PMID: 15860850.
    Citations: 82     Fields:    Translation:HumansCTClinical Trials
  158. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology. 2005 May; 65(5 Suppl):9-16; discussion 17. PMID: 15885273.
    Citations: 9     Fields:    Translation:Humans
  159. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 01; 11(1):284-9. PMID: 15671557.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  160. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5. PMID: 15535434.
    Citations:    Fields:    Translation:Humans
  161. Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol. 2004 Nov; 172(5 Pt 2):S52-6; discussion S56-7. PMID: 15535444.
    Citations: 9     Fields:    Translation:Humans
  162. Michaelson MD, Rosenthal DI, Smith MR. Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma. J Clin Oncol. 2004 Oct 15; 22(20):4233-4. PMID: 15483039.
    Citations: 2     Fields:    Translation:Humans
  163. Smith MR. Osteoclast-targeted therapy for prostate cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):367-75. PMID: 15341675.
    Citations: 2     Fields:    Translation:HumansCells
  164. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 01; 101(7):1569-74. PMID: 15468186.
    Citations: 41     Fields:    Translation:HumansCTClinical Trials
  165. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7. PMID: 15464919.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  166. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. PMID: 15289492.
    Citations: 25     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  167. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004 Aug; 89(8):3841-6. PMID: 15292315.
    Citations: 69     Fields:    Translation:HumansCTClinical Trials
  168. Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004 Aug 01; 101(3):541-9. PMID: 15274067.
    Citations: 25     Fields:    Translation:Humans
  169. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004 Jul 01; 22(13):2546-53. PMID: 15226323.
    Citations: 49     Fields:    Translation:HumansCTClinical Trials
  170. Smith MR. The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy. Oncology (Williston Park). 2004 May; 18(5 Suppl 3):21-5. PMID: 15202584.
    Citations: 1     Fields:    Translation:Humans
  171. Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004 Apr 15; 10(8):2705-8. PMID: 15102674.
    Citations: 13     Fields:    Translation:HumansCells
  172. Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004 Apr; 63(4):742-5. PMID: 15072892.
    Citations: 69     Fields:    Translation:HumansCTClinical Trials
  173. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004 Mar 01; 100(5):892-9. PMID: 14983482.
    Citations: 59     Fields:    Translation:Humans
  174. Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S55-7; discussion S57-8. PMID: 14610411.
    Citations: 2     Fields:    Translation:Humans
  175. Michaelson MD, Smith MR, Talcott JA. Prostate cancer (metastatic). Clin Evid. 2003 Dec; (10):1012-22. PMID: 15555135.
    Citations:    Fields:    Translation:Humans
  176. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. PMID: 14610403.
    Citations:    Fields:    Translation:Humans
  177. Smith MR. Antitumor activity of bisphosphonates. Clin Cancer Res. 2003 Nov 15; 9(15):5433-4. PMID: 14654520.
    Citations: 3     Fields:    Translation:HumansAnimals
  178. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Dec 01; 21(23):4277-84. PMID: 14581438.
    Citations: 64     Fields:    Translation:HumansCTClinical Trials
  179. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003 Jul; 62(1):99-104. PMID: 12837431.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  180. Smith MR. Changes in body composition during hormonal therapy for prostate cancer. Clin Prostate Cancer. 2003 Jun; 2(1):18-21. PMID: 15046678.
    Citations: 7     Fields:    Translation:Humans
  181. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003 Jun; 169(6):2008-12. PMID: 12771706.
    Citations: 150     Fields:    Translation:HumansCTClinical Trials
  182. Smith MR. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 2003 Jun; 29(3):211-8. PMID: 12787715.
    Citations: 3     Fields:    Translation:Humans
  183. Michaelson MD, Smith MR. The role of bisphosphonates in the management of metastatic prostate cancer. Curr Oncol Rep. 2003 May; 5(3):245-9. PMID: 12667423.
    Citations: 2     Fields:    Translation:Humans
  184. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003 Feb 01; 97(3 Suppl):789-95. PMID: 12548577.
    Citations: 10     Fields:    Translation:Humans
  185. Smith MR, Fallon MA, Goode MJ. Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology. 2003 Jan; 61(1):127-31. PMID: 12559282.
    Citations: 10     Fields:    Translation:HumansCells
  186. Michaelson MD, Smith MR. Genitourinary malignancies. Cancer Chemother Biol Response Modif. 2003; 21:547-64. PMID: 15338763.
    Citations: 2     Fields:    Translation:Humans
  187. Smith MR. Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs Aging. 2003; 20(3):175-83. PMID: 12578398.
    Citations: 6     Fields:    Translation:Humans
  188. Michaelson MD, Talcott JA, Smith MR. Prostate cancer: metastatic. Clin Evid. 2002 Dec; (8):881-90. PMID: 12603918.
    Citations:    Fields:    Translation:Humans
  189. Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology. 2002 Nov-Dec; 11(6):518-23. PMID: 12476433.
    Citations: 31     Fields:    Translation:Humans
  190. Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer. 2002 Nov 01; 95(9):1864-8. PMID: 12404279.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  191. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. PMID: 12231036.
    Citations: 8     Fields:    Translation:Humans
  192. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PMID: 12231056.
    Citations: 14     Fields:    Translation:Humans
  193. Smith MR, Fuchs V, Anderson EJ, Fallon MA, Manola J. Measurement of body fat by dual-energy X-ray absorptiometry and bioimpedance analysis in men with prostate cancer. Nutrition. 2002 Jul-Aug; 18(7-8):574-7. PMID: 12093432.
    Citations: 2     Fields:    Translation:Humans
  194. Smith MR, Kantoff PW. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer. Invest New Drugs. 2002 May; 20(2):195-200. PMID: 12099579.